81
IRUS Total
Downloads
  Altmetric

Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study

File Description SizeFormat 
Submission EHJ 20130628.pdfAccepted version3.24 MBAdobe PDFView/Open
Title: Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study
Authors: Gyberg, V
Kotseva, K
Dallongeville, J
De Backer, G
Mellbin, L
Ryden, L
Wood, D
De Bacquer, D
Item Type: Journal Article
Abstract: Purpose: The aim was to investigate the use of cardioprotective drug therapies (aspirin or other antiplatelet agents, β-blockade, renin-angiotensin-aldosterone-system-blockade (RAAS-blockade) and statins) and treatment targets achieved in a large cohort of patients with established coronary artery disease and diabetes across Europe. Methods and results: EUROASPIRE III is an observational cross-sectional study of stable coronary artery disease patients aged 18–80 years from 76 centres in 22 European countries conducted in 2006–2007. The glycaemic status (prevalent, incident or no diabetes), the guideline treatment targets achieved and the use of pharmacotherapies were assessed at one visit 6-36 months after the index event. Of all 6588 patients investigated (women 25%), 4295 (65%) had no diabetes, 752 (11%) had incident diabetes and 1541 (23%) had prevalent diabetes. All four drugs were used in 44% of the patients with no diabetes, 51% with incident diabetes and 50% with prevalent diabetes respectively. Individual prescriptions for patients with no, incident and prevalent diabetes were respectively: aspirin or other antiplatelet agents 91, 93, and 91%; β-blockers: 81, 84, and 79%; RAAS-blockers: 77, 76, and 68%; statins: 80, 80, and 79%. The proportion of patients with coronary artery disease and prevalent diabetes reaching the treatment targets were 20% for blood pressure, 53% for low density lipoprotein cholesterol (LDL-cholesterol) and 22% for haemoglobin A1c (HbA1c). Conclusion: This European study demonstrates a low use of cardioprotective drug therapies among patients with a combination of coronary artery disease and diabetes, which will be contributing to the poor achievement of risk factor treatment targets for cardiovascular prevention.
Issue Date: 1-Apr-2015
Date of Acceptance: 4-Mar-2014
URI: http://hdl.handle.net/10044/1/57448
DOI: https://dx.doi.org/10.1177/2047487314529353
ISSN: 2047-4873
Publisher: SAGE Publications
Start Page: 753
End Page: 761
Journal / Book Title: European Journal of Preventive Cardiology
Volume: 22
Issue: 6
Copyright Statement: © The European Society of Cardiology 2014. Reprinted by permission of SAGE Publications.
Keywords: Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
Cardiovascular disease
diabetes mellitus
secondary prevention
EUROASPIRE
CARDIOVASCULAR-DISEASE
EURO HEART
MYOCARDIAL-INFARCTION
GLUCOSE REGULATION
RISK-FACTORS
PREVENTION
MANAGEMENT
MORTALITY
MELLITUS
CARE
Adolescent
Adrenergic beta-Antagonists
Adult
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Biomarkers
Blood Glucose
Cardiovascular Agents
Coronary Artery Disease
Cross-Sectional Studies
Diabetes Mellitus
Europe
Female
Glycated Hemoglobin A
Guideline Adherence
Health Care Surveys
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Incidence
Male
Middle Aged
Platelet Aggregation Inhibitors
Practice Guidelines as Topic
Practice Patterns, Physicians'
Treatment Outcome
Young Adult
EUROASPIRE Study Group
Hemoglobin A, Glycosylated
Publication Status: Published
Appears in Collections:National Heart and Lung Institute